Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients

Life Sciences

Volumn 87, Issue 3-4, 2010, Pages 83-91

  Sharma, Gayatri ^a,b   Mirza, Sameer ^a   Parshad, Rajinder ^a   Srivastava, Anurag ^a   Gupta, Siddartha Datta ^a   Pandya, Pranav ^b   Ralhan, Ranju ^a,c,d  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Dev Sanskriti Vishwa Vidhyalaya   (India)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

BRCA1; Breast cancer; DNA methylation; Gene silencing; GSTP1; MGMT

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PATIENT; DNA METHYLATION; DNA REPAIR; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SERUM; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 77954247556     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.05.001     Document Type: Article

References (52)

1. Ahuja N., Issa J.P. Aging, methylation and cancer. Histology and Histopathology 2000, 15(3):835-842.
2. Arai T., Miyoshi Y., Kim S.J., Taguchi T., Tamaki Y., Noguchi S. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Research and Treatment 2006, 100(2):169-176.
3. Bae Y.K., Brown A., Garrett E., Bornman D., Fackler M.J., Sukumar S., Herman J.G., Gabrielson E. Hypermethylation in histologically distinct classes of breast cancer. Clinical Cancer Research 2004, 10(18 Pt 1):5998-6005.
4. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nature Review Cancer 2006, 6(2):107-116.
5. Belinsky S.A., Liechty K.C., Gentry F.D., Wolf H.J., Rogers J., Vu K., Haney J., Kennedy T.C., Hirsch F.R., Miller Y., Franklin W.A., Herman J.G., Baylin S.B., Bunn P.A., Byers T. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Research 2006, 66(6):3338-3344.
6. Birgisdottir V., Stefansson O.A., Bodvarsdottir S.K., Hilmarsdottir H., Jonasson J.G., Eyfjord J.E. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Research 2006, 8(4):R38.
7. Catteau A., Morris J.R. BRCA1 methylation: a significant role in tumour development?. Seminars in Cancer Biology 2002, 12(5):359-371.
8. Coles B.F., Kadlubar F.F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs?. Biofactors 2003, 17(1-4):115-130.
9. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomaki P., Lang J.C., Schuller D.E., Yu L., Bloomfield C.D., Caligiuri M.A., Yates A., Nishikawa R., Su Huang H., Petrelli N.J., Zhang X., O'Dorisio M.S., Held W.A., Cavenee W.K., Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics 2000, 24(2):132-138.
10. Danam R.P., Howell S.R., Brent T.P., Harris L.C. Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Molecular Cancer Therapeutics 2005, 4(1):61-69.
11. Daniels D.S., Woo T.T., Luu K.X., Noll D.M., Clarke N.D., Pegg A.E., Tainer J.A. DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nature Structural and Molecular Biology 2004, 11(8):714-720.
12. Dulaimi E., Hillinck J., Ibanez de Caceres I., Al-Saleem T., Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clinical Cancer Research 2004, 10(18 Pt 1):6189-6193.
13. Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. European Journal of Cancer 2000, 36(18):2294-2300.
14. Esteller M. Epigenetics in cancer. New England Journal of Medicine 2008, 358(11):1148-1159.
15. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. Journal of the National Cancer Institute 2000, 92(7):564-569.
16. Euhus D.M., Bu D., Ashfaq R., Xie X.J., Bian A., Leitch A.M., Lewis C.M. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. Cancer Epidemiology, Biomarkers and Prevention 2007, 16(9):1812-1821.
17. Fiegl H., Millinger S., Mueller-Holzner E., Marth C., Ensinger C., Berger A., Klocker H., Goebel G., Widschwendter M. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Research 2005, 65(4):1141-1145.
18. Fraga M.F., Herranz M., Espada J., Ballestar E., Paz M.F., Ropero S., Erkek E., Bozdogan O., Peinado H., Niveleau A., Mao J.H., Balmain A., Cano A., Esteller M. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Research 2004, 64(16):5527-5534.
19. Frommer M., McDonald L.E., Millar D.S., Collis C.M., Watt F., Grigg G.W., Molloy P.L., Paul C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proceedings of National Academy of Sciences USA 1992, 89(5):1827-1831.
20. Garcia J.M., Silva J., Pena C., Garcia V., Rodriguez R., Cruz M.A., Cantos B., Provencio M., Espana P., Bonilla F. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes, Chromosomes and Cancer 2004, 41(2):117-124.
21. Gonzalgo M.L., Pavlovich C.P., Lee S.M., Nelson W.G. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clinical Cancer Research 2003, 9(7):2673-2677.
22. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411(6835):366-374.
23. Jacinto F.V., Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 2007, 22(4):247-253.
24. Jeong D.H., Youm M.Y., Kim Y.N., Lee K.B., Sung M.S., Yoon H.K., Kim K.T. Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. International Journal of Gynecological Cancer 2006, 16(3):1234-1240.
25. Jing F., Jun L., Yong Z., Wang Y., Fei X., Zhang J., Hu L. Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology 2008, 75(1-2):60-66.
26. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
27. Laird P.W. The power and the promise of DNA methylation markers. Nature Reviews Cancer 2003, 3(4):253-266.
28. Lewis C.M., Cler L.R., Bu D.W., Zochbauer-Muller S., Milchgrub S., Naftalis E.Z., Leitch A.M., Minna J.D., Euhus D.M. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clinical Cancer Research 2005, 11(1):166-172.
29. Lopez J., Percharde M., Coley H.M., Webb A., Crook T. The context and potential of epigenetics in oncology. British Journal of Cancer 2009, 100(4):571-577.
30. Mehrotra J., Vali M., McVeigh M., Kominsky S.L., Fackler M.J., Lahti-Domenici J., Polyak K., Sacchi N., Garrett-Mayer E., Argani P., Sukumar S. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clinical Cancer Research 2004, 10(9):3104-3109.
31. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71.
32. Mirza S., Sharma G., Prasad C.P., Parshad R., Srivastava A., Gupta S.D., Ralhan R. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sciences 2007, 81(4):280-287.
33. Miyoshi Y., Murase K., Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. International Journal of Clinical Oncology 2008, 13(5):395-400.
34. Muller H.M., Widschwendter A., Fiegl H., Ivarsson L., Goebel G., Perkmann E., Marth C., Widschwendter M. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Research 2003, 63(22):7641-7645.
35. Osanai T., Takagi Y., Toriya Y., Nakagawa T., Aruga T., Iida S., Uetake H., Sugihara K. Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Japanese Journal of Clinical Oncology 2005, 35(3):121-125.
36. Parrella P., Poeta M.L., Gallo A.P., Prencipe M., Scintu M., Apicella A., Rossiello R., Liguoro G., Seripa D., Gravina C., Rabitti C., Rinaldi M., Nicol T., Tommasi S., Paradiso A., Schittulli F., Altomare V., Fazio V.M. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clinical Cancer Research 2004, 10(16):5349-5354.
37. Pertschuk L.P., Kim D.S., Nayer K., Feldman J.G., Eisenberg K.B., Carter A.C., Rong Z.T., Thelmo W.L., Fleisher J., Greene G.L. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990, 66(8):1663-1670.
38. Qi J., Zhu Y.Q., Huang M.F., Yang D. Hypermethylation of CpG island in O6-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor. World Journal of Gastroenterology 2005, 11(13):2022-2025.
39. Ralhan R., Kaur J., Kreienberg R., Wiesmuller L. Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Letters 2007, 248(1):1-17.
40. Rhodes A., Jasani B., Anderson E., Dodson A.R., Balaton A.J. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. American Journal of Clinical Pathology 2002, 118(3):408-417.
41. Ronneberg J.A., Tost J., Solvang H.K., Alnaes G.I., Johansen F.E., Brendeford E.M., Yakhini Z., Gut I.G., Lonning P.E., Borresen-Dale A.L., Gabrielsen O.S., Kristensen V.N. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Research 2008, 68(14):5562-5571.
42. Sharma G., Mirza S., Prasad C.P., Srivastava A., Gupta S.D., Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sciences 2007, 80(20):1873-1881.
43. Shinozaki M., Hoon D.S., Giuliano A.E., Hansen N.M., Wang H.J., Turner R., Taback B. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clinical Cancer Research 2005, 11(6):2156-2162.
44. Shukla S., Mirza S., Sharma G., Parshad R., Gupta S.D., Ralhan R. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 2006, 1(2):88-93.
45. Soejima H., Zhao W., Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochemistry and Cell Biology 2005, 83(4):429-437.
46. Suijkerbuijk K.P., van der Wall E., Vooijs M., van Diest P.J. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 2008, 75(2):149-152.
47. Szyf M., Pakneshan P., Rabbani S.A. DNA methylation and breast cancer. Biochemical Pharmacology 2004, 68(6):1187-1197.
48. Taback B., Giuliano A.E., Lai R., Hansen N., Singer F.R., Pantel K., Hoon D.S. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Annals of New York of Academy of Sciences 2006, 1075:211-221.
49. Tao M.H., Shields P.G., Nie J., Millen A., Ambrosone C.B., Edge S.B., Krishnan S.S., Marian C., Xie B., Winston J., Vito D., Trevisan M., Freudenheim J.L. DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Research and Treatment 2009, 114(3):559-568.
50. Tapia T., Smalley S.V., Kohen P., Munoz A., Solis L.M., Corvalan A., Faundez P., Devoto L., Camus M., Alvarez M., Carvallo P. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics 2008, 3(3):157-163.
51. Van der Auwera I., Elst H.J., Van Laere S.J., Maes H., Huget P., van Dam P., Van Marck E.A., Vermeulen P.B., Dirix L.Y. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. British Journal of Cancer 2009, 100(8):1277-1286.
52. Wiley A., Katsaros D., Chen H., Rigault de la Longrais I.A., Beeghly A., Puopolo M., Singal R., Zhang Y., Amoako A., Zelterman D., Yu H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006, 107(2):299-308.